Javelin Pharmaceuticals Dyloject(R) Added To Hospital Formulary In UK

Javelin Pharmaceuticals, Inc. (AMEX:JAV) announced late yesterday at its New York analyst and investor day that the UK approval of Dyloject (its proprietary injectable formulation of diclofenac sodium) heralds its emergence as a commercial entity. Previously a specialty pharmaceutical company engaged in the development of pain products, it is now fully engaged in commercialization and revenue generation. [click link for full article]

More: continued here

Filed under: Pain / Anesthetics on December 20th, 2007